{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:36Z","timestamp":1790957916231,"version":"4.1.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>\n                    <jats:underline>Abstract:<\/jats:underline>\n                  <\/jats:title>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of patients with mild-to-moderate atopic dermatitis (AD).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    To assess the efficacy and safety of crisaborole in patients with AD who had received prior treatment with (\n                    <jats:italic toggle=\"yes\">a<\/jats:italic>\n                    ) corticosteroids (systemic or topical) or topical calcineurin inhibitors (TCIs) or (\n                    <jats:italic toggle=\"yes\">b<\/jats:italic>\n                    ) topical corticosteroids (TCSs) or TCIs or (\n                    <jats:italic toggle=\"yes\">c<\/jats:italic>\n                    ) who were treatment-naive (TN).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    This post hoc analysis comprised patients aged \u22652 years with mild-to-moderate AD. Patients were assigned (2:1) to receive crisaborole or vehicle twice daily for 28 days. Patient response was assessed with the Investigator's Static Global Assessment (ISGA), Dermatology Life Quality Index (DLQI), Children's Dermatology Life Quality Index (CDLQI), and Dermatitis Family Impact (DFI) tools. Safety was also assessed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    A significantly higher percentage of patients treated with crisaborole versus vehicle achieved ISGA success regardless of treatment history. Patients treated with crisaborole had significant reductions in DLQI, CDLQI, and DFI scores versus those who received vehicle regardless of treatment history, with the exception of DLQI and DFI scores in the TN group. Crisaborole was well tolerated in all subgroups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Crisaborole demonstrated a favorable efficacy and safety profile in both treatment-experienced and TN patients. ClinicalTrials.gov, NCT02118766 and NCT02118792\n                  <\/jats:p>","DOI":"10.1089\/derm.2023.0112","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T11:58:06Z","timestamp":1704974286000},"page":"84-91","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Crisaborole in Treatment-Experienced Patients with Mild-to-Moderate Atopic Dermatitis"],"prefix":"10.1177","volume":"35","author":[{"given":"Linda F.","family":"Stein Gold","sequence":"first","affiliation":[{"name":"From the,  Henry Ford Health System, Detroit, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wynnis L.","family":"Tom","sequence":"additional","affiliation":[{"name":"University of California San Diego and Rady Children's Hospital-San Diego, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanders","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd., Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbo","family":"Zang","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Vlahos","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Collegeville, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Cha","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.046"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.010"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2010.22.2.125"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedn.2019.03.018"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943640"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00748-2"},{"issue":"1","key":"e_1_3_1_9_2","first-page":"116","article-title":"Guidelines of care for the management of atopic dermatitis: section 2","volume":"71","author":"Eichenfield LF","year":"2014","unstructured":"Eichenfield LF, , Tom WL, , Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol., 2014; 71(1):116\u2013132.","journal-title":"Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol."},{"issue":"12","key":"e_1_3_1_10_2","first-page":"133","article-title":"Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families","volume":"6","author":"Na CH","year":"2019","unstructured":"Na CH, , Chung J, , Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019; 6(12):133.","journal-title":"Children (Basel)"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.09.076"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15366"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.325"},{"key":"e_1_3_1_14_2","first-page":"21S","article-title":"Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document","volume":"22","author":"Dhadwal G","year":"2018","unstructured":"Dhadwal G, , Albrecht L, , Gniadecki R, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section IV: treatment options for the management of atopic dermatitis. J Cutan Med Surg., 2018; 22(1_,suppl):21S\u201329S.","journal-title":"Section IV: treatment options for the management of atopic dermatitis. J Cutan Med Surg."},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/8755122519844507"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046476"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00750-5"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.02.002"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.09.060"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.009"},{"key":"e_1_3_1_22_2","volume-title":"STAQUIS\u2122 (Crisaborole)","author":"Pfizer Australia Pty Ltd","year":"2019","unstructured":"Pfizer Australia Pty Ltd. STAQUIS\u2122 (Crisaborole). Sydney, Australia: Pfizer Australia Pty Ltd.; 2019."},{"key":"e_1_3_1_23_2","volume-title":"EUCRISA (Crisaborole) Ointment, 2% for Topical Use Phosphodiesterase-4 (PDE-4) Inhibitor","author":"Pfizer Inc","year":"2018","unstructured":"Pfizer Inc. EUCRISA (Crisaborole) Ointment, 2% for Topical Use Phosphodiesterase-4 (PDE-4) Inhibitor. Kirkland, Quebec: Pfizer, Canada, Inc.; 2018."},{"key":"e_1_3_1_24_2","volume-title":"Staquis\u2122 (Crisaborole) Ointment, for Topical Use","author":"Pfizer Inc","year":"2020","unstructured":"Pfizer Inc. Staquis\u2122 (Crisaborole) Ointment, for Topical Use. New York, NY: Pfizer, Inc.; 2020."},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555924447"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00506-y"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000013"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.6.763"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249824"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11174974"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb07242.x"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1789050"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.013"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192443"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2023.0112","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:07:11Z","timestamp":1777399631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2023.0112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["10.1089\/derm.2023.0112"],"URL":"https:\/\/doi.org\/10.1089\/derm.2023.0112","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}